and Song et al. [3] in Nature describe a novel, transplantation-free strategy to repair an injured heart through in vivo lineage reprogramming, which might circumvent several of the problems associated with transplantation of exogenous cells.
Lineage reprogramming describes the conversion of differentiated cells directly into other somatic cell types, without first "de-differentiating" the originating cells into a pluripotent intermediate population. This general concept was first clearly established by the conversion of fibroblasts to skeletal myoblasts by the forced expression of MyoD in 1987, and was followed by more examples of lineage reprogramming, including conversion of B lymphocytes to macrophages, inner ear support cells to hair cells, exocrine pancreatic cells to endocrine β-cells, and fibroblasts to neurons [4] .
A lineage reprogramming strategy for conversion of fibroblasts to cardiomyocytes was first reported by Ieda et al. in 2010 [5] . Lineage reprogramming of fibroblasts into cardiomyocytes is a theoretically compelling solution to the clinical problem of fibroblast proliferation and scar formation after myocardial infarction. Scar formation is associated with both a decrease in cardiac pump function and an increase in the frequency of arrhythmias. Ieda et al. [5] demonstrated that cultured mouse fibroblasts could be converted to cardiomyocyte-like cells in vitro through ectopic expression of three cardiogenic transcription factors: Gata4, Mef2c and Tbx5 (GMT). However, the efficiency of such a conversion seemed extremely low. Few cells in which the aforementioned transcription factors were expressed adopted a phenotype resembling that of a cardiomyocyte. Song et al. [3] reported that addition of a fourth factor, Hand2, could increase the efficiency of the conversion. Even with four factors (GHMT), the conversion efficiency was low (~1%).
It was proposed that the low efficiency of in vitro lineage reprogramming could be due to the lack of a natural environment for cardiomyocytes [2, 3] . Based on this assumption, it might follow that factors present in vivo would promote the conversion toward cardiomyocytes and maintenance of the mature phenotype. In addition, in vivo reprogramming can avoid several problems associated with transplantation. Therefore, it would be interesting to test the feasibility of reprogramming cardiac fibroblasts to cardiomyocytes in vivo. Indeed, Qian et al. [2] and Song et al. [3] reported that in vivo lineage reprogramming of fibroblasts into cardiomyocytes was possible, and the efficiency was significantly higher (up to 12%) than in vitro. Both groups performed lineage reprogramming by injection of retroviral particles containing the cardiogenic transcription factor genes (GMT for Qian et These studies conform to the concept of lineage reprogramming; however, it has been suggested that interpretation of "reprogramming" results ought to be approached with caution [6] . Authentic reprogramming events would require the resetting of the epigenome in the parental cells, demonstrated by the adoption of the molecular and cellular features of the destination cell type, including patterns of epigenetic markers, gene expression, morphology and functionality, which should be stable on a long-term basis. Ectopic expression of some transcription factors can activate their direct or indirect downstream targets, especially when they are in a genetic network, as is the case for several transcription factors in the cardiomyocyte lineage [7] . Activation of tissue-specific genes or the gain of certain phenotypic features of the destination cells can be a reflection of partial lineage reprogramming, which can result in a spectrum of intermediate phenotypes with various degrees of similarity to the defined destination cell type, as observed by Song et al. [3] . Chen et al. [8] and Protze et al. [9] recently contended that the three factors (GMT) used by Ieda et al. [5] could activate the expression of a subset of cardiac genes in fibroblasts, but the cells were not completely converted to cardiomyocytes in vitro. On the other hand, Jaywawardena et al. [10] reported that the transient expression of a single microRNA could convert fibroblasts to cardiomyocyte-like cells. It appears that multiple combinations of transcription factors or microRNA(s) can lead fibroblasts to gain certain features of cardiomyocytes, although a more detailed understanding of the lineage reprogramming process will be required in order to distinguish between genuine cardiomyocytes and cardiomyocyte-like cells. It will become particularly important to document the relative extent of differentiation of these cardiomyocytelike cells, as well as their maturity (fetal versus adult), stability and durability of normal function, and long-term survival.
As with any new, exciting therapeutic regenerative strategy, a number of hurdles will need to be passed before lineage reprogramming can be considered as a viable therapeutic strategy for cardiac regeneration. It will be necessary to demonstrate that expression of a small number of transcription factors can be used to convert human fibroblasts into cardiomyocytes (as Qian et al. and Song et al. demonstrated in mouse fibroblasts). One of the central challenges to any type of nucleotide-based therapy has been in vivo delivery systems, particularly those that can achieve a level of efficiency of gene delivery in an interventional (catheter-based) versus surgical approach. In the studies published by Qian et al. and Song et al., retroviruses were used to introduce the transgenes into the infarction area. The retroviral integration in general has been shown to increase the incidence of cancer, as demonstrated in several cases of retrovirus-based gene therapy [11] . It will be necessary to find a safe, non-integrative method to induce the reprogramming in vivo. Once a safer delivery agent is identified, its efficiency will need to be assessed.
While a reduction in scar burden may improve pump function, one of the central problems in heart failure is the onset of life-threatening ventricular arrhythmias that can arise from electrical heterogeneity of the cardiomyocytes within the intact myocardium. It is generally accepted that the substrate of arrhythmias associated with ischemic cardiomyopathy is based on zones of slow conduction that are comprised of viable cardiomyocytes interdigitated with fibroblasts and connective tissue [12] . Since it is likely that there will be topographically heterogeneous lineage distribution arising from the in vivo reprogramming driven by the 3-4 genes, it will be important to examine whether there is an increased risk of arrhythmias in larger animal model systems where this can be thoroughly examined.
Nevertheless, the in vivo reprogramming techniques described by Qian et al. and Song et al. may be the groundwork of a novel strategy to treat degenerative heart disease. The disparity between the in vitro and in vivo efficiency points to critical paracrine factors that may be required for this process, and that may have effects comparable to the combinatorial gene cocktail itself. This approach joins an exciting list of novel therapeutic approaches being developed to attempt to drive heart regeneration, including autologous and allogeneic non-cardiac cell-based therapy [1] , expansions of rare endogenous heart cells for autologous therapy [1] , design of heart patches from pluripotent stem cells [13] , and the transplantation of heart progenitors and/or their differentiated cell types from pluripotent cell lines [14, 15] . A convergence of the fields of cardiac developmental biology, heart stem cell biology, tissue engineering, interventional device delivery technology, and npg cardiovascular clinical medicine is on the horizon. Given the complexity of this goal and the diversity of technology required, it is likely that interdisciplinary teams will be required, i.e., an Apollo mission for heart regenerative therapeutics. For heart failure patients worldwide, this would clearly be "one small step for man, and a giant leap for mankind".
